SynthesisPloS one2012
Variants in exon 11 of MEF2A gene and coronary artery disease: evidence from a case-control study, systematic review, and meta-analysis.
Synthesis in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Association of A561C and G98T polymorphisms in E-selectin gene with coronary artery disease: a meta-analysis.PloS one · 2013Pooled it
- Meta-analyses of KIF6 Trp719Arg in coronary heart disease and statin therapeutic effect.PloS one · 2012Pooled it
- Myocyte Enhancer Factor-2A Gene Mutation and Coronary Artery Disease.Chinese medical journal · 2015Trial
- Association between MEF2A variants and ischemic stroke risk: a case-control study and two prospective cohort studies in a Chinese population.BMC cardiovascular disorders · 2026Article
- Article
- Rare and common coding variants in lipid metabolism-related genes and their association with coronary artery disease.BMC cardiovascular disorders · 2024Article
- Myocyte Enhancer Factor 2A Plays a Central Role in the Regulatory Networks of Cellular Physiopathology.Aging and disease · 2023Review
- Article
- Involvement of myocyte enhancer factor 2c in the pathogenesis of autism spectrum disorder.Heliyon · 2021Review
- The Performance of a Spherical-tip Catheter for Stent Post-dilation: Finite Element Analysis and Experiments.Frontiers in physiology · 2021Article
- Inflammation as a risk factor for stroke in atrial fibrillation: data from a microarray data analysis.The Journal of international medical research · 2020Article
- Article
- MEF2A alters the proliferation, inflammation-related gene expression profiles and its silencing induces cellular senescence in human coronary endothelial cells.BMC molecular biology · 2019Article
- Variants in3 Biotech · 2018Article
- Whole genome sequencing of an African American family highlights toll like receptor 6 variants in Kawasaki disease susceptibility.PloS one · 2017Article
- Genetics of coronary artery disease and myocardial infarction.World journal of cardiology · 2016Review
- Myocardial Infarction-Associated SNP at 6p24 Interferes With MEF2 Binding and Associates With PHACTR1 Expression Levels in Human Coronary Arteries.Arteriosclerosis, thrombosis, and vascular biology · 2015Article
- RNA interference of myocyte enhancer factor 2A accelerates atherosclerosis in apolipoprotein E-deficient mice.PloS one · 2015Article
- Association of MEF2A gene polymorphisms with coronary artery disease.Iranian Red Crescent medical journal · 2014Article
- Mutation in ST6GALNAC5 identified in family with coronary artery disease.Scientific reports · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCoronary artery disease (CAD) is the most common heart disease worldwide. Association of CAD with variants in the myocyte enhancer factor 2A (MEF2A) gene, the first identified CAD-causing gene, has attracted special attention but the results are controversial. We aimed to evaluate this genetic association via a case-control study and meta-analysis. METHODOLOGY/PRINCIPAL
findingsWe performed a case-control association study to investigate the relationship between variations in exon 11 of MEF2A gene and CAD in 1045 sporadic patients and 1008 controls enrolled angiographically among southern Chinese population, and then the data from this study were compared and discussed in a systematic review and meta-analysis with all available published studies on MEF2A gene and CAD. In total, eight variants were identified (21-bp deletion, CAG repeats, CCG repeats, a CCA deletion and four SNPs). No significant link was observed between the common (CAG)(n) polymorphism and CAD, whereas the rare 21-bp deletion was detected only in five affected individuals. The meta-analysis of (CAG)(n) polymorphism and CAD risk, including nine studies with 3801 CAD patients and 4020 controls, also provided no convincing evidence for the genetic association, even upon stratification by race (mainly Whites and Chinese). However, the 21-bp deletion was regarded as a potentially logical, albeit undetermined, candidate for CAD in the following systematic review. CONCLUSIONS/SIGNIFICANCE: Our findings failed to demonstrate a correlation between (CAG)(n) polymorphism with CAD, however, we concluded that the rare 21-bp deletion might have a more compelling effect on CAD than the common (CAG)(n) polymorphism, and MEF2A genetic variant might be a rare but specific cause of CAD/MI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.